UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000024643 |
|---|---|
| Receipt number | R000028349 |
| Scientific Title | A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501) |
| Date of disclosure of the study information | 2016/10/31 |
| Last modified on | 2021/03/30 15:18:31 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501)
Acronym
A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501)
Scientific Title
A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501)
Scientific Title:Acronym
A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501)
Region
| Japan |
Condition
Condition
Thymic carcinoma
Classification by specialty
| Medicine in general | Pneumology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
We investigate the efficacy and the safety of S-1 plus cisplatin with concurrent radiation in patients with locally advanced thymic carcinoma.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
response rate
Key secondary outcomes
Overall survival (OS)
Progression free survival (PFS) Adverse event (AE)
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
1) S-1 is orally administered twice a day at day 1-14 and day 29-42.
Dose of S-1: 80mg/m2/day, 40mg/m2/dose x 2 times
2) Cisplatin 60 mg/m2/day at day 1 and day29.
3) Daily radiation at 2.0 Gy/time from day 1 for 5times /weeks, total 30 times. Total radiation 60Gy.
If the apparent effect of tumor reduction is observed by protocol treatment and a surgical resection is ethically required, surgical resection is applicable.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1.Patients with thymic carcinoma confirmed histologically.
2.Patients without treatment history of chemotherapy, radiation and surgical resection for thymic carcinoma.
3.Patients with unresectable locally advanced cancer and with Masaoka stage classification, stage III.
Eligible for only metastasis to supraclavicular fossa or mediastinal lymph node with Masaoka stage classification, stage IVb.
4.Patients who is judged that radical irradiation is possible by a treatment plan of radiotherapist.
5.Patients without active double cancer.
6.Patient is at least 20 years of age (at enrollment date).
7.Performance status (ECOG): 0-1
8.The latest clinical laboratory test within 14 days prior to enrollment (it is eligible on the same day 2 weeks before the enrolment day) meets the following all standard.
1)WBC >= 3000/mm3 or neutrophil count >=1,500/mm3
2)Hemoglobin >= 9.0g/dL
3)Platelet count>= 100,000/mm3
4)AST, ALT < 100 IU/L
5)Total bilirubin <= 1.5mg/dL
6)Creatinine clearance >= 60 mL/min (Cockcroft-Gault method, 24 hrs method)
7)PaO2 >= 60 Torr or SpO2 >= 90%
9.Patients providing the written informed consent.
10.Patients with life expectancy of at least 3 months.
Key exclusion criteria
1. Patients who requires urgent radiation therapy with a symptom of superior vena cava syndrome.
2. Patients with serious complications : such as uncontrollable angina pectoris, myocardial infarction within 3 months and heart failure, uncontrollable diabetes mellitus,hypertension and serious infection.
3. Patients with interstitial pneumonia confirmed by chest X-ray.
4. Patients having complications judged to affect the enforcement of treatment.
5. Patients with anamnesis of severe hypersensitivity.
6. Patients with pregnant or possibly pregnant.Patients with nursing.
7. Patients who are different for the participation in the study by complication of mental disease or psychiatric symptom.
8. Any other patients who are regarded as unsuitable for this study by the investigators.
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Minoru Fukuda |
Organization
Nagasaki University Hospital
Division name
Clinical Oncology Center
Zip code
Address
1-7-1 Sakamoto, Nagasaki 852-8501, Japan
TEL
095-819-7779
mifukuda258@nifty.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | (1)Minoru Fukuda (2) Takuya Yamazaki |
Organization
Nagasaki University Hospital
Division name
(1)Clinical Oncology Center (2) Department of Radiological Sciences
Zip code
Address
1-7-1 Sakamoto, Nagasaki 852-8501, Japan
TEL
095-819-7779
Homepage URL
mifukuda258@nifty.com
Sponsor or person
Institute
Clinical Research Support Center Kyushu
Institute
Department
Personal name
Funding Source
Organization
Clinical Research Support Center Kyushu
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
1) Lung Oncology Group in Kyushu (LOGIK)
2) Japanese Association for Research on the Thymus (JART)
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
長崎大学（長崎県）
飯塚病院（福岡県）
九州大学（福岡県）国立病院機構大牟田病院（福岡県）
国立病院機構九州がんセンター （福岡県）国立病院機構福岡東医療センター（福岡県）
福岡大学 （福岡県）
佐賀大学 （佐賀県）
熊本大学（熊本県）
熊本地域医療センター（熊本県）
熊本中央病院（熊本県）
宮崎県立宮崎病院（宮崎県）
鹿児島市立病院（宮崎県）
鹿児島大学（鹿児島県）
国立病院機構沖縄病院（沖縄県）
下関市立市民病院（山口県）
沖縄県立南部医療センター・こども医療センター（沖縄県）
国立病院機構岩国医療センター（山口県）
国立病院機構近畿中央胸部疾患センター（大阪府）
大分大学（大分県）
大阪大学大学院医学系研究科（大阪府）
京都府立医科大学（京都府）
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 10 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2016 | Year | 09 | Month | 26 | Day |
Date of IRB
| 2016 | Year | 11 | Month | 29 | Day |
Anticipated trial start date
| 2017 | Year | 01 | Month | 31 | Day |
Last follow-up date
| 2020 | Year | 10 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 10 | Month | 31 | Day |
Last modified on
| 2021 | Year | 03 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028349
